## FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL							
OMB Number:	3235-0287						
Estimated average	burden						
nours per response	e 0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)															
Name and Address of Reporting Person*  Cohen Yuval				Sussing Page 2. Issuer Name and Ticker or Trading Symbol Corbus Pharmaceuticals Holdings, Inc. [CRBP]							5	5. Relationship of Reporting Person(s) to Issuer  (Check all applicable)  _X_ Director _X_ Officer (give title below) Other (specify below)  Chief Executive Officer					
(Last) (First) (Middle) C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 500 RIVER RIDGE DRIVE				3. Date of Earliest Transaction (Month/Day/Year) 03/09/2022									Cnie	I Executive	Jincer		
NORWOOD, MA 02062			4. If Amendment, Date Original Filed(Month/Day/Year)								6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting PersonForm filed by More than One Reporting Person						
(City	)	(State)	(Zip)	Table I - Non-Derivative Securities Acqui							cquir	ired, Disposed of, or Beneficially Owned					
(Instr. 3) Date			2A. Deemo Execution any (Month/Da	Date, i	(Instr. 8)		(A) or Disposed of (Instr. 3, 4 and 5)		d of ( 5)	(D)	Beneficially Owned For Reported Transaction (Instr. 3 and 4)		ollowing	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Common Stock 03/09/2022			P			8,600	A	\$ 0.3	37	83,930		D					
Reminder:	Report on a s	separate line fo	r each class of secur					Pers cont the f	ons what ained i	no respo n this fo splays a	orm a cu	are rren	not requ tly valid	OMB conf	ormation spond unle trol numbe	ss	1474 (9-02)
			Table II - I	Derivative S e.g., puts, c				,		,		•	y Owned				
Derivative Conversion Date Security or Exercise (Month/Day/Year)		Execution Day Year) any	Transaction Code Year) (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			U S	7. Title and Amount of Underlying Securities (Instr. 3 and 4)			9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Owners Form o Derivat Security Direct ( or Indir	Beneficia Ownershi y: (Instr. 4)	
				Cod	e V	(A)	(D)	Date Exer	e rcisable	Expirati Date	ion 7	Γitle	Amount or Number of Shares				

### **Reporting Owners**

				Relationships						
Reporting Owner N		Director	10% Owner	Officer	Other					
Cohen Yuval C/O CORBUS PHARMACEU 500 RIVER RIDGE DRIVE NORWOOD, MA 02062	TICALS HOLDINGS, INC	X		Chief Executive Officer						

### Signatures

/s/ Yuval Cohen	03/09/2022
**Signature of Reporting Person	Date

#### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.